Molecular Biomarkers in Localized Prostate Cancer

Publication Date: December 12, 2019
Last Updated: March 27, 2023

Introduction

Prostate cancer is the most commonly diagnosed cancer in men in the United States (~174,650 in 2019), nearly 20% of all new cancers, and the second leading cause of cancer-related death (~31,620 in 2019).

At diagnosis, there is a diverse spectrum of clinical course ranging from indolent features with a negligible likelihood of morbidity or mortality to characteristics reflecting near certitude of eventual metastases and cancer-specific death.

Predicting future clinical behavior is imperfect but constitutes the foundation of physician counseling and patient management decisions.
A variety of molecular biomarkers have been developed, evaluated, and commercialized with an overarching aim to further personalize risk stratification, more comprehensively inform management decisions, and consequently improve quality of care.

Diagnosis

Commercially available molecular biomarkers (i.e., Oncotype Dx Prostate, Prolaris, Decipher, ProMark) may be offered in situations where the assay result, when considered in toto with routine clinical factors, is likely to impact management. Routine ordering of molecular biomarkers is not recommended. ( EB , I , M )
6539

Overview

Title

Molecular Biomarkers in Localized Prostate Cancer

Authoring Organization